Condition: Non-small Cell Lung Cancer · Sponsor: AstraZeneca
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Los Angeles, California, United States | Completed |
| Research Site | Grand Junction, Colorado, United States | Withdrawn |
| Research Site | Wheat Ridge, Colorado, United States | Withdrawn |
| Research Site | Baltimore, Maryland, United States | Withdrawn |
| Research Site | Detroit, Michigan, United States | Withdrawn |
| Research Site | Chapel Hill, North Carolina, United States | Active Not Recruiting |
| Research Site | Tacoma, Washington, United States | Withdrawn |
| Research Site | Montreal, Quebec, Canada | Withdrawn |
| Research Site | Beijing, China | Recruiting |
| Research Site | Hangzhou, China | Recruiting |
| Research Site | Jinan, China | Recruiting |
| Research Site | Yantai, China | Recruiting |
+ 65 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06448754